adamantane has been researched along with Complications of Diabetes Mellitus in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Azoulay, L; Bouganim, N; Platt, RW; Rouette, J; Yin, H; Yu, OHY | 1 |
| Arya, DS; Bhargava, P; Bhatia, J; Kumar, R; Suchal, K | 1 |
| Chmelik, M; Harreiter, J; Kautzky-Willer, A; Kosi-Trebotic, L; Thomas, A; Trattnig, S | 1 |
| Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Mitka, M | 1 |
| Calado, F; Carvalho, D; Gruenberger, JB; Johal, S; Ong, SH; Silva-Nunes, J; Viana, R; Viriato, D | 1 |
| Chen, YM; Lin, S; Lu, HY; Mu, PW; Shu, J; Wang, MM; Xie, RY; Zeng, LY; Zhang, YJ | 1 |
| Hulshof, TA; Luijendijk, HJ | 1 |
| Bode, BW | 1 |
| Cobble, ME; Frederich, R | 1 |
| Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V | 1 |
3 review(s) available for adamantane and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles | 2009 |
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Patient Safety; Proportional Hazards Models; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
2 trial(s) available for adamantane and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Monitoring; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Treatment Outcome | 2018 |
Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
Topics: Acarbose; Adamantane; Aged; Aged, 80 and over; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
7 other study(ies) available for adamantane and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Topics: Adamantane; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incidence; Incretins; Linagliptin; Liraglutide; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Factors; Sitagliptin Phosphate; Smoking | 2020 |
Targeting AGE-RAGE signaling pathway by Saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats.
Topics: Adamantane; Animals; Apoptosis; Diabetes Complications; Diabetes Mellitus, Experimental; Dipeptides; Heart Diseases; Isoproterenol; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Signal Transduction | 2021 |
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2017 |
New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
Topics: Adamantane; Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Approval; Humans; Hypoglycemic Agents; Piperidines; Uracil | 2013 |
Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Topics: Adamantane; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Nitriles; Portugal; Prospective Studies; Pyrrolidines; Quality-Adjusted Life Years; Risk Factors; Sulfonylurea Compounds; Vildagliptin | 2014 |
Baseline differences in the SAVOR trial.
Topics: Adamantane; Biomedical Research; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Randomized Controlled Trials as Topic; Research Design; Risk; Selection Bias; United States; United States Food and Drug Administration | 2015 |
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
Topics: Adamantane; Animals; Blood Glucose; Blotting, Western; Calcium Signaling; Crosses, Genetic; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Diseases; Hypoglycemic Agents; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Myofibrils; Rats; Rats, Sprague-Dawley; Rats, Zucker; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Time Factors; Urea | 2012 |